AGN
Director Trades
| Date | Director | Value |
|---|
Company News
Argenica Therapeutics Releases Positive Safety Data from Phase 2 ARG-007 Stroke Trial
Perth-based biotech Argenica Therapeutics (ASX: AGN) has released top-line safety results from its Phase 2 trial evaluating lead candidate ARG-007 on patients with acute ischaemic stroke (AIS) who are undergoing mechanical removal of a blood clot in the brain. The multi-centre, double-blind, randomised, placebo-controlled, single-dose clinical study conducted by the company’s clinical research organisation ProPharma […]
Argenica Therapeutics gains ethics approval for phase 1 clinical trial of stroke drug ARG-007
Perth-based biotechnology company Argenica Therapeutics (ASX: AGN) has gained ethics approval to commence a pivotal phase 1 clinical trial of lead drug ARG-007 in healthy participants. ARG-007 is being developed as a novel therapeutic to reduce brain tissue death after stroke with potential to enhance recovery once a stroke has taken place. Approval for the […]
Argenica Therapeutics reports positive findings from peer-reviewed study of stroke drug ARG-007
Biotechnology company Argenica Therapeutics (ASX: AGN) has announced positive findings from an international peer-reviewed study assessing the safety of its lead drug ARG-007 to reduce brain tissue death after stroke. The study was published in the online Journal of Biochemistry and Biophysics Reports by Argenica chief scientific officer Professor Bruno Meloni, in partnership with research […]
Argenica Therapeutics tops up bank balance with $5.5m placement to advance ARG-007 in other neurological conditions
Argenica Therapeutics (ASX: AGN) has topped up its cash reserves with a $5.5 million placement to advance development of its lead drug ARG-007 for other applications beyond stroke. The move follows a number of successful pre-clinical studies evaluating ARG-007 in hypoxic-ischaemic encephalopathy (HIE), traumatic brain injury (TBI), and global cerebral ischaemia. According to Argenica, the […]
Argenica Therapeutics moves closer to phase 1 in-human trials of ARG-007 for stroke
Perth-based biotech company Argenica Therapeutics (ASX: AGN) has completed the final pharmacokinetic (PK) study into the effects of lead candidate ARG-007 on the bodily functions of stroke patients. The rodent-based study was essential in determining how the drug is absorbed, distributed, metabolised and excreted by the body and helped establish appropriate dosing regimes for a […]
Argenica steps closer to clinical studies of stroke drug ARG-007 following positive preclinical safety results
Preclinical safety studies have been successfully completed for Argenica Therapeutics’ (ASX: AGN) stroke drug ARG-007, which paves the way for an ethics submission for a phase one clinical trial. Argenica’s drug ARG-007 has been developed to reduce brain tissue death after stroke and safety pharmacology preclinical studies have led to “no abnormal symptoms” being observed. […]
Argenica Therapeutics toxicology studies indicate key findings ahead of ARG-007 clinical trial
Argenica Therapeutics (ASX: AGN) has announced results of recent in-life rodent and non-human primate toxicology studies, showing success in determining the maximum tolerated dose of ARG-007, required for the phase one clinical trial ethics approval. The Perth-based biotechnology company, in a bid to develop novel therapeutics to reduce brain tissue death after stroke, has made […]
Argenica Therapeutics records positive results from ARG-007 study into cerebral ischaemia
Argenica Therapeutics (ASX: AGN) has recorded positive results from a pre-clinical study assessing the efficacy of lead candidate ARG-007 in protecting brain cells following cerebral ischaemia (or blood flow disruption) caused by cardiac arrest and certain heart surgeries. Utilising a four-vessel occlusion (4-VO) rat model, the study found that when the drug is administered after […]
Argenica Therapeutics publishes scientific paper on ARG-007 ahead of clinical trials
Biotechnology company Argenica Therapeutics (ASX: AGN) has announced its chief scientific officer Professor Bruno Meloni has published a peer-reviewed paper on the company’s lead neuroprotective asset, ARG-007. The paper, entitled Impact of poly-arginine peptides R18D and R18 on alteplase and Tenecteplase thrombolysis in vitro, and neuroprotective stability to proteolysis, is now published in the Journal […]
Argenica Therapeutics moves closer to clinical trials after completing genotoxicity studies on ARG-007
Argenica Therapeutics’ (ASX: AGN) upcoming clinical trials for its lead stroke treatment drug ARG-007 are a step closer with the company completing final good laboratory practice (GLP) genotoxicity studies. The studies have provided key data supporting the safety and tolerability of ARG-007 for the upcoming phase 1 clinical trial. Argenica engaged Medicilon to carry out […]
